Scholarlink

<p>This study aimed to investigate the potential molecular mechanism of BYHWD in treating epilepsy by regulating the adenosine system, based on network pharmacology, molecular docking, and molecular dynamics simulations. Active components of BYHWD and their targets were screened using databases such as TCMSP and SwissTargetPrediction. Epilepsy-related targets were obtained from GeneCards and OMIM. Compound-target networks and protein–protein interaction (PPI) networks were constructed. GO and KEGG enrichment analyses were performed. Molecular docking and molecular dynamics simulations were employed to validate the binding ability and stability of key components with adenosine receptors (ADORA1, ADORA2A). A total of 33 active components targeting adenosine receptors were screened, among which 13 components could simultaneously act on both ADORA1 and ADORA2A. Enrichment analysis suggested that the mechanism involves neuroactive ligand-receptor interaction, cAMP signaling pathway, and synaptic function regulation. Molecular docking showed that multiple components had high affinity for the receptors. Molecular dynamics simulations further confirmed the stable binding of isorhamnetin with ADORA2A, with a binding free energy of −26.51&#xa0;kcal/mol. BYHWD exerts anti-epileptic effects by synergistically regulating adenosine receptors (ADORA1, ADORA2A) and their downstream signaling pathways through multiple active components, thereby restoring the excitatory/inhibitory balance of the neural network.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A study on the mechanism of Buyang Huanwu Decoction in treating epilepsy by regulating adenosine levels

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月8日

查看全文
  • Wu Sitong,
  • Deng Yuhan,
  • Yang Jiayue,
  • Peng Zhuoling,
  • Chen Jiatong

摘要

This study aimed to investigate the potential molecular mechanism of BYHWD in treating epilepsy by regulating the adenosine system, based on network pharmacology, molecular docking, and molecular dynamics simulations. Active components of BYHWD and their targets were screened using databases such as TCMSP and SwissTargetPrediction. Epilepsy-related targets were obtained from GeneCards and OMIM. Compound-target networks and protein–protein interaction (PPI) networks were constructed. GO and KEGG enrichment analyses were performed. Molecular docking and molecular dynamics simulations were employed to validate the binding ability and stability of key components with adenosine receptors (ADORA1, ADORA2A). A total of 33 active components targeting adenosine receptors were screened, among which 13 components could simultaneously act on both ADORA1 and ADORA2A. Enrichment analysis suggested that the mechanism involves neuroactive ligand-receptor interaction, cAMP signaling pathway, and synaptic function regulation. Molecular docking showed that multiple components had high affinity for the receptors. Molecular dynamics simulations further confirmed the stable binding of isorhamnetin with ADORA2A, with a binding free energy of −26.51 kcal/mol. BYHWD exerts anti-epileptic effects by synergistically regulating adenosine receptors (ADORA1, ADORA2A) and their downstream signaling pathways through multiple active components, thereby restoring the excitatory/inhibitory balance of the neural network.